Mucopolysaccharidosis type I
Last updated 27 Feb 2023
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Mucopolysaccharidosis type I (MPS I) is a condition that affects many parts of the body. This disorder was once divided into three separate syndromes: Hurler syndrome (MPS I-H), Hurler-Scheie syndrome (MPS I-H/S), and Scheie syndrome (MPS I-S), listed from most to least severe. Because there is so much overlap between each of these three syndromes, MPS I is currently divided into the severe and attenuated types.
Video picks for Genetic conditionsVideo library
Description
Mucopolysaccharidosis type I (MPS I) is a condition that affects many parts of the body. This disorder was once divided into three separate syndromes: Hurler syndrome (MPS I-H), Hurler-Scheie syndrome (MPS I-H/S), and Scheie syndrome (MPS I-S), listed from most to least severe. Because there is so much overlap between each of these three syndromes, MPS I is currently divided into the severe and attenuated types.
Children with MPS I often have no signs or symptoms of the condition at birth, although some have a soft out-pouching around the belly-button (umbilical hernia) or lower abdomen (inguinal hernia). People with severe MPS I generally begin to show other signs and symptoms of the disorder within the first year of life, while those with the attenuated form have milder features that develop later in childhood.
Individuals with MPS I may have a large head (macrocephaly), a buildup of fluid in the brain (hydrocephalus), heart valve abnormalities, distinctive-looking facial features that are described as "coarse," an enlarged liver and spleen (hepatosplenomegaly), and a large tongue (macroglossia). Vocal cords can also enlarge, resulting in a deep, hoarse voice. The airway may become narrow in some people with MPS I, causing frequent upper respiratory infections and short pauses in breathing during sleep (sleep apnea).
People with MPS I often develop clouding of the clear covering of the eye (cornea), which can cause significant vision loss. Affected individuals may also have hearing loss and recurrent ear infections.
Some individuals with MPS I have short stature and joint deformities (contractures) that affect mobility. Most people with the severe form of the disorder also have dysostosis multiplex, which refers to multiple skeletal abnormalities seen on x-ray. Carpal tunnel syndrome develops in many children with this disorder and is characterised by numbness, tingling, and weakness in the hand and fingers. Narrowing of the spinal canal (spinal stenosis) in the neck can compress and damage the spinal cord.
While both forms of MPS I can affect many different organs and tissues, people with severe MPS I experience a decline in intellectual function and a more rapid disease progression. Developmental delay is usually present by age 1, and severely affected individuals eventually lose basic functional skills (developmentally regress). Children with this form of the disorder usually have a shortened lifespan, sometimes living only into late childhood. Individuals with attenuated MPS I typically live into adulthood and may or may not have a shortened lifespan. Some people with the attenuated type have learning disabilities, while others have no intellectual impairments. Heart disease and airway obstruction are major causes of death in people with both types of MPS I.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal recessive. More than one pattern can apply in different cases.
Related genes
Other names
Hurler syndrome
Hurler-Scheie syndrome
IDUA deficiency
MPS I
MPS I H
MPS I H-S
MPS I S
Mucopolysaccharidosis I
Scheie syndrome
Patient picks for Genetic conditions

Tests and investigations
Blood groups and types
ABO and rhesus are both types of antigens found on the surface of red blood cells. There are lots of other types but these are the most important.
by Dr Rosalyn Adleman, MRCGP

Diabetes
MHRA approves teplizumab to delay progression of type 1 diabetes
Teplizumab (Tzield) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to help delay the onset of Stage 3 type 1 diabetes (T1D). Read on to see what this means if you are prescribed teplizumab and what it does for you.
by Lawrence Higgins

Diabetes
Adam Smith on mindfulness, mental health, and diabetes
Sky Sports presenter Adam Smith was diagnosed with type 1 diabetes just as his career was taking off. I caught up with Adam to discuss a day in his life and the challenges of managing the condition while working in the fast-paced world of live television. We also spoke about his support for the Mind in Range Collection, created in partnership with Omnipod and Calm. Adam shares how he uses mindfulness as a practical tool to help navigate the daily stresses of living with type 1 diabetes.
by Victoria Raw

Health and wellness video library
Type 1 diabetes videos
Our type 1 diabetes video hub features expert-led videos covering everything you need to know—from what causes type 1 diabetes and its common symptoms, to how it’s treated and the possible complications to watch out for. Whether you’re newly diagnosed or supporting someone with the condition, these videos are here to help you take control and live well.
by Lawrence Higgins

Diabetes
What is diabulimia?
When our children are tiny, we sometimes feel helpless - perhaps at 4 am when they're crying inconsolably or have been coughing for hours. Yet at least we know exactly what's going on, because we're in charge of every aspect of their lives. How much harder it is when our children are no longer entirely dependent and we have to rely on them to make the right choices.
by Dr Sarah Jarvis

Diabetes
Type 1 diabetes
Type 1 diabetes is the type of diabetes that typically develops in children and in young adults. In type 1 diabetes the body stops making insulin and the blood sugar (glucose) level goes very high. Treatment to control the blood glucose level is with insulin injections and a healthy diet. Other treatments aim to reduce the risk of complications. They include reducing blood pressure if it is high and advice to lead a healthy lifestyle.
by Dr Colin Tidy, MRCGP
Related patient information and medicines

Patient information leaflet
Glycogen storage disorders
Glycogen storage disorders are a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to glycogen, or the breakdown of glycogen back into glucose. They mostly tend to affect your liver and muscles. Newer treatment possibilities provide hope for an improved outlook.

Patient information leaflet
Childhood leukaemias
Leukaemia is a cancer of the cells which develop into blood cells. The outlook (prognosis) for children with leukaemia is usually very good and most children are cured. This leaflet gives a general overview of childhood leukaemias. Leukaemia is a cancer of cells in the bone marrow (the cells which develop into blood cells). Cancer is a disease of.

Patient information leaflet
Mouth cancer
Mouth cancer is a cancer that can develop in any part of the mouth, including the tongue, the gums, the palate (roof of the mouth), under the tongue, the skin lining the mouth or the lips. Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a diagnosis or.

Patient information leaflet
Ehlers-Danlos syndrome
The Ehlers-Danlos syndromes (EDS) are a group of conditions that affect the stretchiness and strength of supporting tissues in the body, including skin, joints, blood vessels and internal organs. What are the Ehlers-Danlos syndromes. The Ehlers Danlos syndromes (EDS) are a group of conditions which are usually (although not always) inherited from.

Patient information leaflet
Muscular dystrophy
If muscular dystrophy is suspected, tests can help to make an accurate diagnosis. Muscular dystrophy cannot be cured but there are various treatments which can help. Muscular dystrophy (MD) is the name given to a group of disorders which cause progressive muscle weakness (meaning it gets worse over time). The different types vary as to how mild or.

Patient information leaflet
Coombs test
A Coombs test is a type of blood test. It is named after the person who invented it, Dr Robin Coombs. There are two types of Coombs test. What is a Coombs test. The two types of Coombs test are as follows: The direct Coombs test involves looking directly at red blood cells found in a sample of blood. The direct Coombs test is sometimes called the.
Further reading and references
- Mucopolysaccharidosis type I; MedlinePlus, National Library of Medicine.
- Campos D, Monaga M. Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms. Metab Brain Dis. 2012 Jun;27(2):121-9. doi: 10.1007/s11011-012-9302-1. Epub 2012 Apr 14.
- Clarke LA. Mucopolysaccharidosis Type I. 2002 Oct 31 [updated 2025 Dec 4]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1162/
- Clarke LA. The mucopolysaccharidoses: a success of molecular medicine. Expert Rev Mol Med. 2008 Jan 18;10:e1. doi: 10.1017/S1462399408000550.
- Moore D, Connock MJ, Wraith E, Lavery C. The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis. 2008 Sep 16;3:24. doi: 10.1186/1750-1172-3-24.
- Muenzer J. The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations. J Pediatr. 2004 May;144(5 Suppl):S27-34. doi: 10.1016/j.jpeds.2004.01.052. No abstract available.
- Pastores GM, Arn P, Beck M, Clarke JT, Guffon N, Kaplan P, Muenzer J, Norato DY, Shapiro E, Thomas J, Viskochil D, Wraith JE. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab. 2007 May;91(1):37-47. doi: 10.1016/j.ymgme.2007.01.011. Epub 2007 Mar 2.
- Terlato NJ, Cox GF. Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet Med. 2003 Jul-Aug;5(4):286-94. doi: 10.1097/01.GIM.0000078027.83236.49.
- Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr. 2005 Jul;94(7):872-7. doi: 10.1111/j.1651-2227.2005.tb02004.x.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

